Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema

Trial Profile

A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs CSL 312 (Primary) ; CSL 312 (Primary)
  • Indications Hereditary angioedema
  • Focus Therapeutic Use
  • Sponsors CSL Behring
  • Most Recent Events

    • 07 Jan 2019 Planned End Date changed from 1 Nov 2020 to 1 Sep 2020.
    • 07 Jan 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Aug 2019.
    • 06 Nov 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top